Serina Therapeutics Stock Price, News & Analysis
Why is SER Stock Down Today?
Company Description
Serina Therapeutics (NYSE: ser) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $26.5M, ranking #6,003 among all listed U.S. companies by market cap.
ser stock has declined 61.8% over the past year. Shares last traded at $2.08.
On a trailing twelve-month basis, Serina Therapeutics reported revenue of $130K with net income of -$19.2M and diluted earnings per share of $-1.91. The company operates at a net profit margin of -14755.4%.
This page provides a comprehensive overview of ser stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Serina Therapeutics (ser) stock last traded at $2.08, down 1.92% from the previous close. Over the past 12 months, the stock has lost 61.8%. At a market capitalization of $26.5M, ser is classified as a micro-cap stock with approximately 12.3M shares outstanding.
Latest News
Serina Therapeutics has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, private placement, clinical trial, fda approval. View all ser news →
SEC Filings
Serina Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 4, 1 Form 10-K/A, 1 Form 10-K. The most recent filing was submitted on March 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ser SEC filings →
Insider Radar
Insider selling at Serina Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Serina Therapeutics generated $130K in revenue over the trailing twelve months, operating income reached -$24.0M (-18478.5% operating margin), and net income was -$19.2M, reflecting a -14755.4% net profit margin. Diluted earnings per share stood at $-1.91. The company generated -$18.0M in operating cash flow. With a current ratio of 1.71, the balance sheet reflects a strong liquidity position.
Upcoming Events
SMC review for Cohort 1
Topline SAD results
Listing compliance cure deadline
Deadline to regain NYSE compliance
Serina Therapeutics has 4 upcoming scheduled events. The next event, "SMC review for Cohort 1", is scheduled for July 1, 2026 (in 83 days). Investors can track these dates to stay informed about potential catalysts that may affect the ser stock price.
Short Interest History
Short interest in Serina Therapeutics (ser) currently stands at 110.5 thousand shares, down 15.1% from the previous reporting period, representing 2.0% of the float. Over the past 12 months, short interest has increased by 340.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Serina Therapeutics (ser) currently stands at 2.0 days, up 102% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 20.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 10.4 days.
ser Company Profile & Sector Positioning
Serina Therapeutics (ser) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NYSE.
Investors comparing ser often look at related companies in the same sector, including Vtv Therapeutics (VTVT), Polypid Ltd. (PYPD), JUPITER NEUROSCIENCES, INC. (JUNS), Relmada Therapeutics Inc (RLMD), and MAIA Biotechnology Inc. (MAIA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ser's relative position within its industry.
Serina Therapeutics (NYSE American: SER), a biotechnology company, said it will present at theApr 7, 2026 5th LNP Formulation & Process Development Summit in Boston, including data that its POZ-lipid did not trigger an antibody response in a rat vaccine-format study and a polymer-lipid for oligonucleotide payloads.
This is a conference presentation and early-stage update, not a disclosed commercial or financial event.